Enlightenment through Data™

Chronic diseases are characterized by periods of relative stability punctuated by episodic events in many diseases such as respiratory diseases.. These episodic events may be more effectively managed if action is taken before they worsen ultimately resulting in hospitalisation. Using proprietary, as well as open source, data capabilities empowered by deep learning we discover and extract relevant actionable information from large complex datasets.

DeepHRV

After training on the retrospective, historical, data we deploy our algorithms to process real-time streaming data from wearables and other medical devices to identify and predict exacerbations. We also combine other additional datasets including proteomic, metabolomic and genomic data to further discover additional patterns.

Our Focus

Zenzium’s initial focus is on chronic diseases like respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma & Cystic Fibrosis (CF). These diseases are all characterized by periods of relative stability under maintenance regimes but are punctuated by episodic exacerbations.  The identification and prediction of these exacerbations is critical in mitigating more serious complications that may ultimately result in hospitalisations. The identification and prediction of exacerbations is also vitally important during clinical trials. Zenzium uses deep learning technology applied to longitudinal (time-series) data to identify and subsequently predict exacerbations.

Although our initial focus is on respiratory conditions the approach is equally applicable to other chronic diseases such as Cardiovascular Disease (CVD), diabetes, arthritis, stroke, multiple sclerosis (MS) and other inflammatory or metabolic conditions. We also believe neurodegenerative conditions such as dementia, specifically Alzheimer’s, could benefit from the approach.

Our Market

Our markets include the pharmaceutical & biopharmaceutical industry, healthcare delivery and self-management segments.

In the pharmaceutical and related industries a critical step is the clinical trial process where managing the trial and achieving the endpoints is a key objective. Zenzium believes identifying and managing exacerbations more objectively can play a vital role. In addition ensuring therapeutic compliance and managing exacerbations is important during a maintenance regimen.

As we deal with an aging population with increasing comorbidities the management of chronic diseases is vitally important to improve patient outcomes, reduce healthcare costs and make better use of scarce healthcare resources. Diseases such as COPD are compounded resulting in increased frequency and severity of exacerbations resulting in irreversible loss of lung function. A key is the management of exacerbations therefore mitigating hospitalisations.

Many of the worlds’ healthcare system are being stretched to their limits from both a financial and resource prespective. Self-management is becoming a critical activity where patients are assuming more responsibility for their own health.

Our Technology

Zenzium has developed an Artificial Intelligence (AI) approach, more specifically a deep learning technology, to identify and predict exacerbations in chronic diseases from physiological and other data. We apply deep learning to multivariate time-series (longitudinal) data that is also aggregated with diagnostic and Electronic Medical Records (EMRs) information as well as proteomic, genomic and metabolomic data. Zenzium has developed key proprietary techniques to handle sparse, noisy and small datasets as those typically encountered in healthcare and biomedical disiplines.. We combine data using our Data Fusion Engine (DFE™) in our secure cloud environment after which we apply deep learning methodologies.

Zenzium has an active research programme investigating areas such as transfer learning as applied to time-series data. We maintain active collaborations and partnerships with leading entities in the AI, machine learning, deep learning, biomedical and high performance computing communities.

Whether you are looking for a solution to catalyse clinical trials, monitor therapeutic compliance, improve patient outcomes or enable self-management, let’s talk…

Headquarters

Zenzium Ltd, Alderley Park, Congleton Road, Nether Alderley, Macclesfield, Cheshire, SK10 4TG, United Kingdom

E: info@zenzium.com

T: +44 (0) 1625 725970